Development Level

Tbio 120 | 10,625
Tdark 27 | 7,003
Tchem 15 | 1,890
Tclin 1 | 602

IMPC Phenotype

preweaning lethality, complete... 12 | 633
decreased circulating choleste... 6 | 85
decreased circulating HDL chol... 5 | 77
embryonic lethality prior to t... 5 | 187
decreased body weight 4 | 174
decreased circulating LDL chol... 4 | 37
decreased caudal vertebrae num... 3 | 49
decreased circulating alanine ... 3 | 53
decreased total body fat amoun... 3 | 186
abnormal lens morphology 2 | 73
decreased circulating free fat... 2 | 39
decreased lactate dehydrogenas... 2 | 14
decreased lumbar vertebrae num... 2 | 62
decreased rib number 2 | 59
decreased startle reflex 2 | 48
embryonic lethality prior to o... 2 | 148
hydrometra 2 | 13
increased hematocrit 2 | 36
increased mean corpuscular hem... 2 | 93
increased sacral vertebrae num... 2 | 62
abnormal behavior 1 | 226
abnormal embryo size 1 | 112
abnormal eye morphology 1 | 38
abnormal gait 1 | 51
abnormal heart morphology 1 | 51
abnormal hindbrain development 1 | 24
abnormal kidney morphology 1 | 30
abnormal midbrain development 1 | 22
abnormal neural tube closure 1 | 37
abnormal retina morphology 1 | 100
abnormal retinal pigmentation 1 | 61
abnormal sacral vertebrae morp... 1 | 5
abnormal skin condition 1 | 6
abnormal testis morphology 1 | 30
abnormal vibrissa morphology 1 | 17
absent vibrissae 1 | 14
cataract 1 | 26
decreased CD11b-low dendritic ... 1 | 3
decreased CD4-positive NK T ce... 1 | 4
decreased CD8-positive, alpha-... 1 | 26
decreased CD8-positive, naive ... 1 | 5
decreased KLRG1-positive NK ce... 1 | 9
decreased Ly6C-positive immatu... 1 | 4
decreased Ly6C-positive mature... 1 | 4
decreased NK T cell number 1 | 28
decreased NK cell number 1 | 16
decreased T cell number 1 | 31
decreased blood urea nitrogen ... 1 | 31
decreased circulating alkaline... 1 | 41
decreased circulating aspartat... 1 | 27
decreased circulating chloride... 1 | 32
decreased circulating creatini... 1 | 31
decreased circulating serum al... 1 | 79
decreased circulating sodium l... 1 | 18
decreased circulating total pr... 1 | 41
decreased circulating triglyce... 1 | 83
decreased effector memory CD4-... 1 | 6
decreased effector memory CD8-... 1 | 24
decreased fasted circulating g... 1 | 49
decreased gamma-delta T cell n... 1 | 18
decreased grip strength 1 | 123
decreased hematocrit 1 | 25
decreased marginal zone B cell... 1 | 1
decreased marginal zone precur... 1 | 1
decreased memory-marker CD4-po... 1 | 4
enlarged heart 1 | 111
enlarged heart atrium 1 | 2
hydrops fetalis 1 | 22
hypoactivity 1 | 89
immune system phenotype 1 | 17
increased CD11b-high dendritic... 1 | 5
increased CD4-negative NK T ce... 1 | 4
increased CD4-positive, alpha ... 1 | 15
increased CD5-positive Ly6C-po... 1 | 4
increased KLRG1-positive CD4-p... 1 | 3
increased KLRG1-positive T-hel... 1 | 2
increased Ly6C high monocyte n... 1 | 12
increased blood urea nitrogen ... 1 | 44
increased circulating alkaline... 1 | 119
increased circulating creatini... 1 | 29
increased circulating free fat... 1 | 17
increased circulating triglyce... 1 | 24
increased effector memory T-he... 1 | 5
increased fasted circulating g... 1 | 68
increased follicular B cell nu... 1 | 1
increased mean corpuscular vol... 1 | 91
increased plasma cell number 1 | 5
short tibia 1 | 82
small testis 1 | 37
straub tail 1 | 26
thrombocytosis 1 | 23

Disease

ovarian cancer 105 | 8,491
osteosarcoma 88 | 7,933
glioblastoma 70 | 5,572
psoriasis 57 | 6,685
medulloblastoma, large-cell 56 | 6,234
atypical teratoid / rhabdoid tumor 50 | 4,369
lung cancer 46 | 4,473
intraductal papillary-mucinous adenoma (IPMA) 37 | 2,956
intraductal papillary-mucinous neoplasm (IPMN) 34 | 3,289
lung adenocarcinoma 33 | 2,714
intraductal papillary-mucinous carcinoma (IPMC) 32 | 2,988
malignant mesothelioma 31 | 3,163
Multiple myeloma 30 | 1,327
pilocytic astrocytoma 30 | 3,086
pancreatic ductal adenocarcinoma liver metastasis 29 | 1,795
Breast cancer 28 | 3,098
ependymoma 28 | 2,514
invasive ductal carcinoma 28 | 2,950
primitive neuroectodermal tumor 28 | 3,031
non-small cell lung cancer 27 | 2,798
pediatric high grade glioma 26 | 2,712
Carcinoma 25 | 2,147
lung carcinoma 25 | 2,844
pancreatic cancer 25 | 2,300
oligodendroglioma 24 | 2,849
diabetes mellitus 22 | 1,663
Pick disease 20 | 1,893
acute quadriplegic myopathy 20 | 1,157
ulcerative colitis 20 | 2,087
adult high grade glioma 19 | 2,148
astrocytic glioma 19 | 2,241
group 4 medulloblastoma 19 | 1,875
astrocytoma 17 | 1,493
breast carcinoma 17 | 1,614
cystic fibrosis 17 | 1,670
non primary Sjogren syndrome sicca 17 | 840
pituitary cancer 17 | 1,972
Cancer 16 | 2,346
Rheumatoid Arthritis 16 | 1,170
posterior fossa group A ependymoma 16 | 1,511
dermatomyositis 15 | 966
interstitial cystitis 15 | 2,299
medulloblastoma 15 | 1,524
sonic hedgehog group medulloblastoma 15 | 1,482
subependymal giant cell astrocytoma 15 | 2,287
cutaneous lupus erythematosus 14 | 1,056
group 3 medulloblastoma 14 | 2,254
hepatocellular carcinoma 14 | 550
spina bifida 14 | 1,064
tuberculosis 14 | 1,563
tuberculosis and treatment for 6 months 14 | 686
juvenile dermatomyositis 13 | 1,189
posterior fossa group B ependymoma 13 | 1,530
active Crohn's disease 12 | 918
pancreatic carcinoma 12 | 567
acute myeloid leukemia 11 | 785
esophageal adenocarcinoma 11 | 737
colon cancer 10 | 1,475
Duchenne muscular dystrophy 9 | 602
Waldenstrons macroglobulinemia 9 | 764
adrenocortical carcinoma 9 | 1,427
primary pancreatic ductal adenocarcinoma 9 | 1,271
Congenital disorder of glycosylation 8 | 53
Intellectual disability 8 | 573
aldosterone-producing adenoma 8 | 664
autosomal dominant Emery-Dreifuss muscular dystrophy 8 | 499
ductal carcinoma in situ 8 | 1,745
gastric cancer 8 | 436
primary Sjogren syndrome 8 | 788
Bipolar Disorder 7 | 266
atypical teratoid/rhabdoid tumor 7 | 1,095
mucosa-associated lymphoid tissue lymphoma 7 | 480
Amyotrophic Lateral Sclerosis 6 | 432
Congenital dyserythropoietic anemia 6 | 17
Down syndrome 6 | 548
Endometriosis 6 | 535
Polycystic Ovary Syndrome 6 | 334
Schizophrenia 6 | 503
gastric carcinoma 6 | 832
nephrosclerosis 6 | 329
tuberculosis and treatment for 3 months 6 | 327
Anemia 5 | 252
Barrett's esophagus 5 | 185
Heart disease 5 | 279
IGA Glomerulonephritis 5 | 454
Neurodegenerative disease 5 | 383
Obesity 5 | 616
Prostatic Neoplasms 5 | 471
Stomach Neoplasms 5 | 282
Vascular disease 5 | 281
fibroadenoma 5 | 557
hereditary spastic paraplegia 5 | 313
inflammatory breast cancer 5 | 404
nasopharyngeal carcinoma 5 | 1,056
non-small cell lung carcinoma 5 | 413
Alzheimer's disease 4 | 644
Atopic dermatitis 4 | 944
Hypersensitivity reaction type II disease 4 | 235
Myocardial Ischemia 4 | 169
chronic rhinosinusitis 4 | 512

Tissue

Cardiovascular System 163 | 17,957
Digestive Tract 163 | 18,472
Endocrine System 163 | 18,511
Female tissues 163 | 18,646
Liver and Pancreas 163 | 18,135
Male tissues 163 | 17,968
Nervous System 163 | 18,560
Urinary Tract 163 | 18,443
Blood and immune system 162 | 17,994
Respiratory system 162 | 17,483
Skin and soft tissues 162 | 18,114

Target Family

Non-IDG 114 | 11,969
Enzyme 46 | 4,146
Ion Channel 1 | 341
Kinase 1 | 634
Transcription Factor 1 | 1,400

Reactome Pathway

Transport to the Golgi and sub... 163 | 163
Signal Transduction 2,515 | 2,515
Immune System 2,183 | 2,183
Metabolism 2,131 | 2,131
Gene Expression 1,754 | 1,754
Metabolism of proteins 1,544 | 1,544
Innate Immune System 1,375 | 1,375
Signaling by GPCR 1,329 | 1,329
Developmental Biology 1,028 | 1,028
GPCR downstream signaling 1,015 | 1,015
Post-translational protein mod... 1,004 | 1,004
Adaptive Immune System 938 | 938
Disease 855 | 855
Generic Transcription Pathway 852 | 852
Cytokine Signaling in Immune s... 803 | 803
Metabolism of lipids and lipop... 797 | 797
Vesicle-mediated transport 705 | 705
Hemostasis 669 | 669
Transmembrane transport of sma... 668 | 668
Membrane Trafficking 608 | 608
Cell Cycle 572 | 572
Neutrophil degranulation 542 | 542
Axon guidance 541 | 541
Signaling by Interleukins 500 | 500
Cell Cycle, Mitotic 470 | 470
Signalling by NGF 467 | 467
GPCR ligand binding 456 | 456
Gastrin-CREB signalling pathwa... 435 | 435
Class I MHC mediated antigen p... 430 | 430
Olfactory Signaling Pathway 430 | 430
Fc epsilon receptor (FCERI) si... 423 | 423
Cellular responses to stress 415 | 415
DAP12 interactions 409 | 409
Infectious disease 391 | 391
NGF signalling via TRKA from t... 378 | 378
Signaling by Rho GTPases 378 | 378
Signaling by PDGF 367 | 367
Diseases of signal transductio... 359 | 359
Transcriptional Regulation by ... 356 | 356
Signaling by EGFR 355 | 355
Metabolism of amino acids and ... 353 | 353
DAP12 signaling 346 | 346
Downstream signal transduction 343 | 343
Neuronal System 343 | 343
Organelle biogenesis and maint... 334 | 334
Signaling by VEGF 329 | 329
Signaling by SCF-KIT 327 | 327
Class A/1 (Rhodopsin-like rece... 322 | 322
VEGFA-VEGFR2 Pathway 321 | 321
FCERI mediated MAPK activation 316 | 316
Signaling by Insulin receptor 312 | 312
Antigen processing: Ubiquitina... 301 | 301
Extracellular matrix organizat... 292 | 292
Signaling by Type 1 Insulin-li... 290 | 290
Signaling by Wnt 290 | 290
IGF1R signaling cascade 289 | 289
IRS-related events triggered b... 289 | 289
Insulin receptor signalling ca... 288 | 288
Metabolism of carbohydrates 288 | 288
DNA Repair 286 | 286
IRS-mediated signalling 285 | 285
MAPK family signaling cascades 283 | 283
Asparagine N-linked glycosylat... 282 | 282
Signaling by the B Cell Recept... 282 | 282
SLC-mediated transmembrane tra... 280 | 280
Deubiquitination 277 | 277
Interferon Signaling 275 | 275
Platelet activation, signaling... 274 | 274
NCAM signaling for neurite out... 268 | 268
M Phase 266 | 266
Interleukin-3, 5 and GM-CSF si... 262 | 262
RET signaling 261 | 261
Signalling to ERKs 254 | 254
Interleukin-2 signaling 253 | 253
Immunoregulatory interactions ... 252 | 252
RHO GTPase Effectors 249 | 249
VEGFR2 mediated cell prolifera... 249 | 249
Signalling to RAS 247 | 247
Interleukin receptor SHC signa... 246 | 246
G alpha (i) signalling events 245 | 245
Fatty acid, triacylglycerol, a... 244 | 244
Signaling by Leptin 244 | 244
Prolonged ERK activation event... 243 | 243
MAPK1/MAPK3 signaling 242 | 242
Frs2-mediated activation 241 | 241
HIV Infection 241 | 241
ARMS-mediated activation 240 | 240
Signalling to p38 via RIT and ... 240 | 240
Chromatin modifying enzymes 237 | 237
Chromatin organization 237 | 237
GRB2 events in EGFR signaling 236 | 236
RAF/MAP kinase cascade 236 | 236
SHC1 events in EGFR signaling 236 | 236
SOS-mediated signalling 236 | 236
Processing of Capped Intron-Co... 235 | 235
Biological oxidations 215 | 215
Keratinization 213 | 213
Transmission across Chemical S... 210 | 210
rRNA processing 209 | 209
Ion channel transport 204 | 204
Phospholipid metabolism 202 | 202

This is where graphics are reside..
Name Gene Development Level Target Family Log Novelty  Pubmed Score  Antibody Count  Knowledge Availability 
Trafficking protein particle complex subunit 9 TRAPPC9 Tbio Non-IDG -2.14008 133.3 71
Alpha-soluble NSF attachment protein NAPA Tbio Non-IDG -1.91708 86.7 133
Folate receptor alpha FOLR1 Tchem Non-IDG -2.27944 181.4 235
Sia-alpha-2,3-Gal-beta-1,4-GlcNAc-R:alpha 2,8-sialyltransferase ST8SIA3 Tbio Enzyme -1.02017 9.88 46
Dipeptidyl peptidase 1 CTSC Tchem Enzyme -3.24582 1740.5 143
Conserved oligomeric Golgi complex subunit 5 COG5 Tbio Non-IDG -0.92957 8.17 15
Alpha-1-antitrypsin SERPINA1 Tbio Non-IDG -3.73976 5495.0 809
Protransforming growth factor alpha TGFA Tbio Non-IDG -2.13802 123.3 575
SEC23-interacting protein SEC23IP Tbio Non-IDG -0.85332 6.51 123
Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase A MGAT4A Tbio Enzyme -1.17545 14.3 63